Literature DB >> 1350936

Disappearance of a pituitary tumor after 15 months of treatment with CV 205-502, a new dopamine agonist.

W J Fassbender1, H Stracke, G Bachmann, W Rau, K Federlin.   

Abstract

We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose of 0.075 mg. Under this low dose, prolactin in the serum normalized after 4 weeks, the initial hormone value being 189.9 ng/ml. After 6 months of therapy there was still a 6 x 6 mm tumor, and after 15 months of treatment the pathological process could no longer be observed with magnetic resonance imaging. In the 20th month of therapy the patient became pregnant. An ovulatory menstrual cycle had been present for a few months.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350936     DOI: 10.1007/bf00235530

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  9 in total

1.  [NMR tomographic diagnosis of microadenomas of the hypophysis: a comparison of MRT, CT and operation].

Authors:  W Wichmann; O Schubiger; A Valavanis; K Kasdaglis
Journal:  Rofo       Date:  1988-09

2.  MR imaging of prolactin-secreting microadenomas.

Authors:  K W Pojunas; D L Daniels; A L Williams; V M Haughton
Journal:  AJNR Am J Neuroradiol       Date:  1986 Mar-Apr       Impact factor: 3.825

Review 3.  Neuroendocrine control of prolactin secretion.

Authors:  D A Leong; L S Frawley; J D Neill
Journal:  Annu Rev Physiol       Date:  1983       Impact factor: 19.318

4.  [Value of nuclear magnetic resonance tomography in the diagnosis and therapy outcome of prolactinomas].

Authors:  U Fink; B Mayr; H K Rjosk; R Oeckler; K von Werder; D Hahn
Journal:  Digitale Bilddiagn       Date:  1985-09

5.  Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.

Authors:  R Nordmann; T J Petcher
Journal:  J Med Chem       Date:  1985-03       Impact factor: 7.446

6.  CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion.

Authors:  C Rasmussen; T Bergh; L Wide; J Brownell
Journal:  Clin Endocrinol (Oxf)       Date:  1987-03       Impact factor: 3.478

7.  Hyperprolactinaemia in amenorrhoea - incidence and clinical significance.

Authors:  T Bergh; S J Nillius; L Wide
Journal:  Acta Endocrinol (Copenh)       Date:  1977-12

8.  Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy.

Authors:  J A Wass; P J Moult; M O Thorner; J E Dacie; M Charlesworth; A E Jones; G M Besser
Journal:  Lancet       Date:  1979-07-14       Impact factor: 79.321

9.  Effects of bromocriptine on pituitary tumour size.

Authors:  A M McGregor; M F Scanlon; R Hall; K Hall
Journal:  Br Med J       Date:  1979-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.